Taysha Gene Therapies (TSHA) has reaffirmed FDA alignment on the Biologics License Application pathway for TSHA-102, including pivotal trial design and the potential use of a six month interim analysis for approval.

The reaffirmed FDA pathway comes after a run in the stock, with a 30 day share price return of 45.95% and a 1 year total shareholder return of 217.62%. This signals strong momentum despite recent earnings losses and ongoing cash burn.

If progress at Taysha has your attention, it can be useful to see what else is moving in gene and biotech related AI, starting with 35 healthcare AI stocks

With TSHA trading at $6.67 after a strong 1 year run, yet still sitting below the average analyst target and some intrinsic value estimates, investors may ask whether there is still a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 42.4% Undervalued

At $6.67, Taysha Gene Therapies trades well below the most followed fair value estimate of $11.57. This estimate reflects detailed analyst assumptions around future earnings and margins.

The analysts have a consensus price target of $11.57 for Taysha Gene Therapies based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $19.0, and the most bearish reporting a price target of just $7.0.

Want to see what kind of revenue swing and margin shift sit behind that valuation gap? This narrative is based on rapid top line expansion and a premium future earnings multiple. Curious how those ingredients combine into an $11.57 fair value and where analysts disagree most strongly?

Result: Fair Value of $11.57 (UNDERVALUED)

However, investors still need to weigh clinical and regulatory setbacks or higher than expected cash burn, which could quickly challenge those upbeat margin and P/E assumptions.

Next Steps

The story so far mixes optimism with clear risks, so do not wait for the next headline to shape your thinking. Review the full picture of 2 key rewards and 3 important warning signs

Looking for more investment ideas?

If this story has sharpened your thinking, do not stop here. Broaden your watchlist with fresh, data driven ideas that could reshape your portfolio.

• Spot potential bargains early by reviewing companies flagged as 50 high quality undervalued stocks before they appear on everyone else's radar.
• Strengthen the defensive side of your portfolio by focusing on businesses highlighted in the solid balance sheet and fundamentals stocks screener (46 results) for financial resilience.
• Get ahead of the crowd by scanning the screener containing 21 high quality undiscovered gems that combine quality fundamentals with lower market attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.